10-Q quarterly report · filed Nov 10, 2026

Cullinan Therapeutics, Inc. (CGEM) Q3 2026 10-Q Quarterly Report

Short answer

Cullinan Therapeutics, Inc. (CGEM) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$49M
+2.4% YoY · +8.0% QoQ

Source: XBRL data from the Cullinan Therapeutics, Inc. (CGEM) Q3 2026 10-Q on SEC EDGAR. USD.

Cullinan Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, no product sales, unchanged from Q3 2025
  • R&D expense $40.2M vs $42.0M YoY, G&A $12.4M vs $13.6M
  • Best pipeline growth: CLN-978 R&D $9.8M vs $5.3M YoY
  • Cash, equivalents, and short-term investments $289.6M, long-term investments and interest receivable $24.2M
  • Operating cash outflow $127.3M, cash expected to fund operations at least twelve months, additional capital may be needed

Risk Factors

  • Newly added SEC compliance risk: non-affiliate market value exceeded $700 million on June 30, 2026
  • Reporting transition: SRC status ends after December 31, 2026, with accommodations continuing for 2027 filings
  • Regulatory burden: accelerated-filer status could require Section 404(b) auditor attestation beginning December 31, 2027
  • Financial risk: additional reporting requirements expected to increase legal, accounting and compliance costs
  • Operational risk: expanded public-company obligations could divert management attention from operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Cullinan Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.